Health Technology · Pharmaceuticals: Major · NSE: SENORES · data 2026-10-09
Senores Pharmaceuticals Ltd.
Health check: Strong (7.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,320
Market cap
₹6,094 cr
P/E
48.2
P/B
—
ROE
13.4%
ROCE
12.6%
Debt / equity
0.37
Dividend yield
0.00%
1-year return
84.1%
52-week high
₹1,599
52-week low
₹705.1
Operating margin
24.5%
Growth
| Revenue (last 12 months) | ₹692 cr |
| Net profit (last 12 months) | ₹126 cr |
| Sales growth, 3 years (yearly) | 161.6% |
| Profit growth, 3 years (yearly) | 139.2% |
Chart patterns
- Double top — forming (key level ₹1,279.7)
Similar companies
Supriya Lifescience Limited (SUPRIYA) · Sanofi India Limited (SANOFI) · Innova Captab Limited (INNOVACAP) · Sun Pharma Advanced Research Co. Ltd. (SPARC) · Orchid Pharma Limited (ORCHPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SENORES in NSE Scanner →